Emirates Drug Establishment approves Lipfendra for high cholesterol, making the UAE the second country in the world to authorise it

On August 1, 2026, the Emirates Drug Establishment (EDE) announced its approval of Lipfendra for the treatment of high low-density lipoprotein cholesterol (LDL-C) in adults, including those with certain genetic predispositions. This oral medication, taken once daily, is intended to reduce LDL-C levels when combined with a balanced diet and physical activity, thereby expanding treatment options for patients requiring additional interventions. The UAE's authorization of Lipfendra makes it the second country globally to approve this treatment. This decision highlights the UAE's regulatory efficiency and its commitment to facilitating patient access to innovative pharmaceutical solutions. The EDE additionally encouraged individuals with high cholesterol to maintain healthy lifestyles and consult with healthcare professionals for appropriate treatment plans.